GEN-MKT-18-7897-A
Mar 28, 2018 | Blogs, Life Science Research, Lipidomics | 0 comments
Lipidomics research has progressed rapidly in the last decade. Twenty years ago, the determination of the lipid composition of a biological sample required slow and extensive multi-dimensional chromatographic separation and chemical derivatization strategies. Today, in-depth analysis can be performed quickly using high throughput analysis by mass spectrometry.
Advances in mass spectrometry have enabled in-depth lipidomic analyses with unparalleled qualitative and quantitative sensitivity. However, unambiguous identification and quantitation of lipid molecular species in total lipid extracts has proven to be difficult, primarily due to isobaric overlapping isobaric and isomeric species. There are greater than 100,000 lipid molecular species present in a typical biological lipid extract that occupy a narrow mass range (~400-1100 amu), making such overlap a significant problem.
SelexION Technology represents the next technological advance and is uniquely suited for lipidomic research. Using Differential Mobility Separation (DMS) as an upfront orthogonal separation enables the resolution of complex lipid mixtures, effectively addressing the problem of isobaric interferences among different lipid classes and sub-classes.
Key Features of SelexION Technology for Lipid Analysis
SelexION Technology is a planar differential mobility device that separates analytes based on differences in their chemical properties, prior to entering the instrument orifice, thus providing an orthogonal level of selectivity.
Read our technical paper to see how we effectively resolves multiple lipid classes from complex mixtures prior to analysis by mass spectrometry. By removing isobaric and isomeric interferences, lipid analysis by QTRAP systems using SelexION Technology enables more confident identification of lipid molecular species and provides for more accurate relative quantitation by MS/MS.
Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.
Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?
As regulatory scrutiny increases and detection requirements tighten, laboratories are facing a new question: How can TFA be measured reliably, sensitively, and at scale?
Posted by
You must be logged in to post a comment.
Share this post with your network